*Juveria Mahveen and Dr. Abdul Mannan


Osteoporosis is a progressive systemic skeletal disease characterized by reduced bone mass/density and micro architectural deterioration of bone tissue. It is a “silent disease” as there are no symptoms prior to a fracture. The prevalence of osteoporosis increases markedly with age. DEXA is regarded as the gold standard technique for diagnosis of osteoporosis. Treatment for osteoporosis should include lifestyle measures including nutrition, exercise and measures to reduce falls. Adequate calcium intake and vitamin D should be provided. Effective pharmacological management strategies should always be implemented where necessary including bisphosphonate such as Alendronate, Etidronate, Risedronate, andraloxifene, strontium ranelate and teriparatide. Postmenopausal osteoporosis may be treated with a bisphosphonate. If bisphosphonates are unsuitable then calcitriol may be considered. Estrogen should only be considered if there is significant risk for osteoporosis and other drugs are not suitable. New biologics agents, Denosumab and Odanacatib are approved for treatment of osteoporosis. Both target osteoclasts to rebalance bone loss and bone building. The prevention of osteoporosis should be considered in early life and should be continued by regular physical activity and a balanced diet.

Keywords: Osteoporosis, Bone Mass Density (BMD), Bone Resorption, Catephsin K Inhibitor, Anti-Sclerostin bodies, Vertebroplasty, Mesenchymal Stem Cells (MSC).

[Full Text Article]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Tangudu Nagabhusana Rao

Download Article : Click here

News & Updation


    APRIL 2019 Issue has been successfully launched on 1 April 2019

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 4.382 to 4.918 due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction